-
Paralytic agents such as vecuronium and cis-atracurium have been used as "rescue therapies" in patients with ARDS for many years, but, as with other rescue strategies including prone mechanical ventilation or inhaled vasodilators, evidence of a mortality benefit from this intervention has been lacking.
-
Although corticosteroids are beneficial in treating severe exacerbations of chronic obstructive pulmonary disease (COPD), studies to date have not shown high-doses (such as methylprednisolone, 2 mg/kg or more per 24 h) administered intravenously (IV) to be superior to lower doses (e.g., prednisone, 40 mg/day) given orally, with respect to clinically important outcomes.
-
In this issue: FDA Advisory Committee recommends approval of dabigatran, safety of proton pump inhibitors, effectiveness of glucosamine and chondroitin, FDA Actions.
-
-
-
Peripheral arterial disease (PAD) is a pathological condition characterized by atherosclerotic occlusion of arterial blood supply to the lower or upper extremities.
-
-
WHO recommendations for antiviral use for H1N1 flu; antibiotic use trends for acute respiratory tract infection; denosumab clears FDA Expert Panel; FDA Actions.
-
Obsessive-compulsive disorders have achieved greater visibility in our society with several well-known celebrities such as Howie Mandel and David Beckham with acknowledged cases. Patients may be reluctant to share their symptoms with their primary care physician for fear of being thought crazy. Hopefully today the increased recognition with celebrities and greater media attention to the disorder will resolve this fear and allow patients to become more open with their doctors.
-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
